B cell depletion at one year is associated with rituximab treatment response in patients with CTD-ILD:an analysis of the RECITAL cohort. - Amsterdam 2025

Interstitial lung disease of known causes: risk factors, detection and management

Chair(s): Antoine Froidure, Punchalee Kaenmuang

Session type: Oral presentation

B cell depletion at one year is associated with rituximab treatment response in patients with CTD-ILD:an analysis of the RECITAL cohort.

Serena Bellani

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Effect of nerandomilast on clinical outcomes in patients with progressive pulmonary fibrosis (PPF): results from the final database lock of the FIBRONEER-ILD trial

Marlies S. Wijsenbeek

Replay

Poster

Abstract

Slides

The working life exposome and incidence of interstitial lung diseases: a Danish national cohort study the EU EPHOR project

Lucile Sese

Replay

Poster

Abstract

Slides

A risk estimation tool for early ILD detection in Sjögren Disease

Anna Maria Hoffmann-vold

Replay

Poster

Abstract

Slides

Plasma Proteome Analysis Identifies Biomarkers Associated with Subclinical RA-ILD

Joyce Lee

Replay

Abstract

Slides

e-Lung Detects Progressive Pulmonary Fibrosis Earlier Than Conventional Tools: Insights from the REVISE-PPF Multicentre Study

Ayodeji Adegunsoye

Replay

Abstract

Slides

High prevalence of lung ultrasound interstitial syndrome in systemic sclerosis patients with normal HRCT and lung function

Benjamin Thoreau

Replay

Poster

Abstract

Slides

Optimizing Photon Counting CT imaging for Interstitial Lung Disease assessment

Cristina Cretu

Replay

Poster

Abstract

Slides

Evolution of Treatment Patterns and Their Impact on Disease Progression in Systemic Sclerosis-associated ILD

Corrado Campochiaro

Replay

Poster

Abstract

Slides

B cell depletion at one year is associated with rituximab treatment response in patients with CTD-ILD:an analysis of the RECITAL cohort.

Serena Bellani

Replay

Poster

Abstract

Slides

Nintedanib for the treatment of Sars-Cov-2 induced pulmonary fibrosis: a randomized clinical trial (Nintecor)

Guillaume Beltramo

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}